Healwell AI: A Story of Soaring Revenue and Persistent Losses

Healwell AI reports explosive 427% revenue growth to CAD 103.8M and first positive adjusted EBITDA, but faces a CAD 39.1M net loss as it targets 50% AI segment growth.

Healwell AI is currently showcasing its strategy to institutional investors at the 38th Annual ROTH Investor Conference in California. The company's narrative is one of explosive top-line growth, yet it remains shadowed by significant bottom-line challenges.

Financial Performance: A Mixed Picture

For the 2025 fiscal year, Healwell AI reported revenue from continuing operations of CAD 103.8 million. This figure represents a staggering 427% increase from the CAD 19.7 million generated in the prior year, a surge primarily driven by the integration of Orion Health. In a notable milestone, the company achieved its first full year of positive adjusted EBITDA, posting CAD 2.3 million compared to a loss of CAD 14.2 million in 2024.

However, this operational progress is contrasted by a substantial IFRS net loss from continuing activities, which totaled CAD 39.1 million. The financials clearly reflect the substantial costs associated with the firm's aggressive expansion and ongoing structural transformation.

Strategic Positioning and Future Targets

Management has outlined specific growth objectives for the current 2026 fiscal year. The AI and Data Science segment is targeted to grow organically by more than 50%, following a year where segment revenue doubled to approximately CAD 10 million. For its Healthcare Software division, Healwell AI is aiming for a 10% increase in recurring revenue.

The company's strategic moves in late 2025 have bolstered its financial flexibility. Divestments completed in the fourth quarter unlocked CAD 9.7 million in liquidity, contributing to a year-end cash position of CAD 18.6 million. Healwell AI is also evaluating the monetization of several strategic holdings, including an interest in an investment vehicle connected to xAI.

Investor Sentiment and Market Performance

Healwell AI's share price has faced considerable pressure, having lost more than half its value since its 52-week high. The central debate among investors now centers on whether the recent turn to positive EBITDA and the ambitious growth roadmap can justify the ongoing net losses, or if the company's transformation continues to demand an unsustainable capital outlay.